Log in

OTCMKTS:POLXFPolydex Pharmaceuticals Stock Price, Forecast & News

$0.99
0.00 (0.00 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.99
Now: $0.99
$0.99
50-Day Range
$0.80
MA: $0.97
$1.05
52-Week Range
$0.80
Now: $0.99
$1.29
VolumeN/A
Average Volume2,633 shs
Market Capitalization$3.39 million
P/E Ratio14.14
Dividend YieldN/A
Beta0.38
Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.77 out of 5 stars


Industry, Sector and Symbol

Industry Industrial inorganic chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:POLXF
CUSIPN/A
Phone416-755-2231

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.14 million
Cash Flow$0.15 per share
Book Value$1.69 per share

Profitability

Net Income$250,000.00

Miscellaneous

Employees23
Market Cap$3.39 million
Next Earnings Date6/15/2020 (Estimated)
OptionableNot Optionable

Receive POLXF News and Ratings via Email

Sign-up to receive the latest news and ratings for POLXF and its competitors with MarketBeat's FREE daily newsletter.

Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions

How has Polydex Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Polydex Pharmaceuticals' stock was trading at $1.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, POLXF shares have decreased by 6.6% and is now trading at $0.99. View which stocks have been most impacted by Coronavirus.

When is Polydex Pharmaceuticals' next earnings date?

Polydex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, June 15th 2020. View our earnings forecast for Polydex Pharmaceuticals.

How were Polydex Pharmaceuticals' earnings last quarter?

Polydex Pharmaceuticals Ltd (OTCMKTS:POLXF) issued its quarterly earnings data on Thursday, April, 30th. The company reported ($0.04) EPS for the quarter. The company earned $1.46 million during the quarter. Polydex Pharmaceuticals had a net margin of 4.88% and a return on equity of 4.22%. View Polydex Pharmaceuticals' earnings history.

Has Polydex Pharmaceuticals been receiving favorable news coverage?

Media stories about POLXF stock have trended negative on Tuesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Polydex Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPolydex Pharmaceuticals.

Who are some of Polydex Pharmaceuticals' key competitors?

Who are Polydex Pharmaceuticals' key executives?

Polydex Pharmaceuticals' management team includes the following people:
  • Mr. George G. Usher, Chairman, CEO & Pres (Age 60)
  • Ms. Sharon L. Wardlaw, COO, Treasurer & Sec. (Age 66)
  • Mr. David Jamestee, Chief Financial Officer

What is Polydex Pharmaceuticals' stock symbol?

Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF."

How do I buy shares of Polydex Pharmaceuticals?

Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Polydex Pharmaceuticals' stock price today?

One share of POLXF stock can currently be purchased for approximately $0.99.

How big of a company is Polydex Pharmaceuticals?

Polydex Pharmaceuticals has a market capitalization of $3.39 million and generates $5.14 million in revenue each year. Polydex Pharmaceuticals employs 23 workers across the globe.

What is Polydex Pharmaceuticals' official website?

The official website for Polydex Pharmaceuticals is www.polydex.com.

How can I contact Polydex Pharmaceuticals?

Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.